Top Page
Recordati Industria Chimica e Farmaceutica SPA
(LSE:REC)
Recordati Industria Chimica e Farmaceutica SPA (REC) vs. iShares MSCI Italy ETF (EWI)
Recordati Industria Chimica e Farmaceutica SPA Business Overview & Revenue Model
Recordati Industria Chimica e Farmaceutica SPA Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.34B | 2.08B | 1.85B | 1.58B | 1.45B |
| Gross Profit | ||||
| 1.60B | 1.42B | 1.29B | 1.15B | 1.04B |
| EBIT | ||||
| 638.90M | 558.01M | 437.33M | 490.19M | 469.02M |
| EBITDA | ||||
| 795.37M | 708.16M | 559.35M | 578.35M | 566.83M |
| Net Income Common Stockholders | ||||
| 416.51M | 389.21M | 312.34M | 385.97M | 354.98M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 322.42M | 221.81M | 284.73M | 244.58M | 188.23M |
| Total Assets | ||||
| 5.13B | 4.21B | 4.00B | 2.82B | 2.71B |
| Total Debt | ||||
| 22.84M | 1.81B | 1.72B | 992.19M | 1.06B |
| Net Debt | ||||
| -299.58M | 1.59B | 1.43B | 747.61M | 872.83M |
| Total Liabilities | ||||
| 3.26B | 2.52B | 2.45B | 1.43B | 1.44B |
| Stockholders Equity | ||||
| 1.88B | 1.69B | 1.55B | 1.38B | 1.28B |
| Cash Flow | Free Cash Flow | |||
| 535.10M | 102.06M | 365.35M | 404.29M | 271.90M |
| Operating Cash Flow | ||||
| 569.92M | 485.32M | 461.69M | 491.65M | 403.57M |
| Investing Cash Flow | ||||
| -844.94M | -379.62M | -767.12M | -87.50M | -131.56M |
| Financing Cash Flow | ||||
| 372.11M | -168.91M | 341.28M | -355.94M | -264.29M |
Recordati Industria Chimica e Farmaceutica SPA Technical Analysis
Recordati Industria Chimica e Farmaceutica SPA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | €11.37B | 27.19 | 22.02% | 2.33% | 12.85% | 7.34% | |
73 Outperform | €5.20B | 28.25 | 11.27% | 1.28% | 3.24% | 17.49% | |
73 Outperform | €657.96M | 20.02 | 39.51% | ― | 219.91% | ― | |
66 Neutral | €486.95M | 29.44 | 1.98% | 17.78% | 63.72% | ||
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% |
Recordati Industria Chimica e Farmaceutica SPA Corporate Events
Recordati announced an update on its share buyback program, which began on April 30, 2025, following a resolution by the Shareholders’ Meeting. The program is intended to purchase shares for stock option and performance share plans for the company’s management. During the period from June 2 to June 6, 2025, Recordati purchased 70,709 ordinary shares, bringing its total holdings to 3,360,825 shares, representing 1.607% of its share capital.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated on its share buyback program initiated in April 2025, aimed at acquiring shares for stock option and performance share plans for management. Between May 26 and May 30, 2025, Recordati purchased 76,378 shares, holding 1.604% of its share capital by the end of May, reflecting its strategic focus on incentivizing management and aligning with shareholder interests.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR55.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has announced an update on its share buyback program initiated on April 30, 2025. The company purchased 89,225 shares between May 19 and May 23, 2025, at an average price of 51.3752 Euros per share. This buyback is part of Recordati’s strategy to allocate shares for stock option and performance share plans for its management, reflecting its commitment to incentivizing its leadership and enhancing shareholder value.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the progress of its share buyback program, initiated on April 30, 2025. The program, which aims to purchase shares for stock option and performance share plans, saw the acquisition of 88,677 ordinary shares between May 12 and May 16, 2025, reflecting the company’s strategic focus on incentivizing management and aligning with future incentive plans.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its stakeholders on the execution of its share buyback program, which was initiated on April 30, 2025. The program aims to purchase shares to support stock options and performance share plans for the management of the Recordati Group. As of May 9, 2025, Recordati has purchased 2,329 ordinary shares at a weighted average price of €52.5512 each, and now holds 3,136,086 own shares, representing 1.500% of its share capital. This strategic move is expected to enhance the company’s incentive plans and align management interests with those of shareholders.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati has reported strong financial performance in the first quarter of 2025, with consolidated net revenues increasing by 11.9% to €680.0 million. The company’s growth is driven by robust performance in its Specialty & Primary Care and Rare Diseases segments, with significant contributions from the extension of Isturisa’s indication and the approval of Signifor LAR in China. The company maintains its financial targets for 2025 and anticipates continued momentum through 2027, supported by strategic growth initiatives and disciplined cost management.
Recordati S.p.A. has updated its shareholders on the execution of its share buyback program, initiated on April 30, 2025, following a resolution from the Shareholders’ Meeting. The program aims to purchase shares to service stock options and performance share plans for the company’s management. As of May 2, 2025, Recordati has acquired 3,103 shares, bringing its total to 3,133,757 own shares, which is 1.499% of its share capital. This strategic move is part of Recordati’s broader efforts to enhance shareholder value and support its incentive plans.
Recordati has released the summary report of the voting results from its Ordinary Shareholders’ Meeting held on April 29, 2025. This report is accessible on the company’s website and through an authorized storage mechanism, reflecting the company’s commitment to transparency and shareholder engagement.
Recordati S.p.A. has announced a program to purchase up to 2,000,000 of its own shares to support stock option and performance share plans for its management. The program, managed by UBS Europe SE, will run until November 7, 2025, with a maximum countervalue of €125 million, aiming to enhance management incentives and potentially impact the company’s market positioning.
Recordati S.p.A. announced the approval of its 2024 financial statements and a dividend increase to €1.27 per share, reflecting a 5.8% rise from the previous year. Additionally, a new Board of Directors was appointed for the 2025-2027 period, with Andrea Recordati and Robert Koremans confirmed as Chairman and CEO, respectively. The company also renewed its authorization to purchase and dispose of treasury shares and approved a new share purchase program to support stock option and performance share plans.
Recordati announced that the FDA has approved the supplemental new drug application for ISTURISA® (osilodrostat) to treat endogenous hypercortisolemia in adults with Cushing’s syndrome who cannot undergo surgery or for whom surgery has not been successful. This approval expands the previous indication for the treatment of patients with Cushing’s disease, a subtype of Cushing’s syndrome, and is supported by a comprehensive clinical development program involving over 350 patients. The extension of ISTURISA®’s indication addresses an important unmet need and is expected to generate significant added value for Recordati, enhancing its position in the rare diseases segment.
Recordati has disclosed transactions involving the sale and purchase of treasury shares. The company sold treasury shares directly to beneficiaries of its stock option plans and executed a share buy-back program through UBS Europe SE, which concluded on March 31, 2025. These transactions are part of Recordati’s strategic financial management, potentially impacting its stock liquidity and shareholder value.
Recordati S.p.A. has concluded its share buyback program, which began on November 12, 2024, and was aimed at purchasing shares to support stock options and performance share plans for management. The company purchased a total of 1,498,369 shares, representing 0.716% of its share capital, for a total value of 79,476,342.59 Euros. As of March 31, 2025, Recordati holds 3,130,654 own shares, equivalent to 1.497% of its share capital.
Recordati has announced the availability of its 2024 Annual Financial Report, including the Draft Financial Statements and Consolidated Financial Statements as of December 31, 2024, along with various management and audit reports. These documents, approved by the Board of Directors, are accessible to the public via the company’s headquarters, website, and authorized storage mechanism. This release is part of the preparations for the Ordinary Shareholders’ Meeting scheduled for April 29, 2025, highlighting the company’s commitment to transparency and governance.
Recordati announced the availability of the Directors’ Report related to the appointment of the Board of Directors, ahead of the Ordinary Shareholders’ Meeting scheduled for April 29, 2025. This move underscores the company’s commitment to transparency and governance, potentially impacting its operations and stakeholder relations positively.
Recordati Industria Chimica e Farmaceutica S.p.A. has announced an Ordinary Meeting of Shareholders scheduled for April 29, 2025. The agenda includes discussions on the financial statements for 2024, the appointment and remuneration of the Board of Directors, and a proposal for the purchase and disposal of treasury shares. This meeting is significant for stakeholders as it will address key governance and financial decisions that could impact the company’s strategic direction and shareholder value.
Recordati S.p.A. reported strong financial results for 2024, with net revenues of €2,341.6 million, a 12.4% increase from the previous year, driven by growth in both specialty and primary care and rare diseases segments. The company proposed a dividend of €1.27 per share and reaffirmed its commitment to ESG objectives, including reducing emissions and enhancing sustainability practices, which are recognized by major ESG indices and ratings.
Recordati has updated its shareholders on the progress of its share buyback program, which was initiated to support stock options and performance share plans for its management. Between March 3 and March 7, 2025, the company purchased 139,592 of its ordinary shares, holding a total of 2,942,785 own shares, equivalent to 1.407% of its share capital. This move is part of Recordati’s strategy to enhance shareholder value and align management incentives with company performance.